Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0041-1728730
Neutrophil-to-Lymphocyte Ratio as an Inflammatory Marker in Familial Mediterranean Fever: A Systematic Review and Meta-analysis
![](https://www.thieme-connect.de/media/10.1055-s-00033103/202101/lookinside/thumbnails/10-1055-s-0041-1728730_2000096-1.jpg)
Abstract
Familial Mediterranean fever (FMF) is a genetic disease with inflammatory basis. Several studies have assessed the role of neutrophil-to-lymphocyte ratio (NLR) in detecting this inflammation; however, no systematic review or meta-analysis has assessed these studies together. The aim of this study is to systematically review and meta-analyze the NLR value between FMF patients and normal controls. Scopus, PubMed, Embase, and ISI Web of Science were searched using predesigned search strategy to find the studies that assessed NLR in FMF patients and compared the value with normal controls. There was no time limitation. Finally, two researchers extracted data including first author name, publication year, the country, study design, number of patients and controls, time of disease diagnosis, FMF diagnostic criteria, mean age of the patients, and the NLR value. The data were systematically reviewed and meta-analyzed. In total, 464 articles were found on search; however, only 12 studies qualified for enrollment in the systematic review and 10 studies, with appropriate effect size, in the meta-analysis. These studies were conducted between 2013 and 2019. Eleven studies were conducted in Turkey and one in Egypt. Out of 12 studies, 9 had enrollment criteria for FMF patients: 8 studies used Tel Hashomer criteria and 1 study used Yalçinkaya–Özen criteria. All studies, except for two, had genetic confirmation for FMF. The mean NLR values in attack-free (standard difference in means = 0.482; p < 0.0001) and attack groups (standard difference in means = 0.853; p = 0.001) were significantly higher than control group. The mean NLR value may be related to the underlying inflammation in FMF.
Publication History
Received: 19 November 2020
Accepted: 08 March 2021
Article published online:
01 June 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Özen S. Update on the epidemiology and disease outcome of familial Mediterranean fever. Best Pract Res Clin Rheumatol 2018; 32 (02) 254-260
- 2 Cekin N, Akyurek ME, Pinarbasi E, Ozen F. MEFV mutations and their relation to major clinical symptoms of familial Mediterranean fever. Gene 2017; 626: 9-13
- 3 Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001; 9 (07) 473-483
- 4 Ozdogan H, Ugurlu S. Familial Mediterranean fever. Presse Med 2019; 48 (1 Pt 2): e61-e76
- 5 Beheshtian M, Izadi N, Kriegshauser G. et al. Prevalence of common MEFV mutations and carrier frequencies in a large cohort of Iranian populations. J Genet 2016; 95 (03) 667-674
- 6 Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43 (02) 227-253
- 7 Barut K, Sahin S, Adrovic A. et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int 2018; 38 (01) 67-74
- 8 Yildirim K, Uzkeser H, Keles M. et al. Relationship between serum interleukin-1β levels and acute phase response proteins in patients with familial Mediterranean fever. Biochem Med (Zagreb) 2012; 22 (01) 109-113
- 9 Uslu AU, Deveci K, Korkmaz S. et al. Is neutrophil/lymphocyte ratio associated with subclinical inflammation and amyloidosis in patients with familial Mediterranean fever?. BioMed Res Int 2013; 2013: 185317
- 10 Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011; 7 (02) 105-112
- 11 Xu S, Ma Y, Wu M. et al. Neutrophil lymphocyte ratio in patients with ankylosing spondylitis: a systematic review and meta-analysis. Mod Rheumatol 2020; 30 (01) 141-148
- 12 Erre GL, Paliogiannis P, Castagna F. et al. Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest 2019; 49 (01) e13037
- 13 Ma L, Zeng A, Chen B, Chen Y, Zhou R. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with systemic lupus erythematosus and their correlation with activity: a meta-analysis. Int Immunopharmacol 2019; 76: 105949
- 14 Ghodsi A, Mirimoghaddam MM, Sarabi M. et al. Neutrophil-to-lymphocyte ratio as a novel and valuable marker for assessing disease severity in ulcerative colitis, multiple sclerosis, and Kawasaki disease: a review. J Basic Res Med Sci 2020; 7 (03) 62-70
- 15 Zhang Z, Su Q, Zhang L, Yang Z, Qiu Y, Mo W. Diagnostic value of hemoglobin and neutrophil-to-lymphocyte ratio in Behcet disease. Medicine (Baltimore) 2019; 98 (52) e18443
- 16 Yorulmaz A, Akbulut H, Taş SA, Tıraş M, Yahya İ, Peru H. Evaluation of hematological parameters in children with FMF. Clin Rheumatol 2019; 38 (03) 701-707
- 17 Basaran O, Uncu N, Celikel BA, Aydın F, Cakar N. Assessment of neutrophil to lymphocyte ratio and mean platelet volume in pediatric familial Mediterranean fever patients. J Res Med Sci 2017; 22: 35
- 18 Kelesoglu FM, Aygun E, Okumus NK. et al. Evaluation of subclinical inflammation in familial Mediterranean fever patients: relations with mutation types and attack status: a retrospective study. Clin Rheumatol 2016; 35 (11) 2757-2763
- 19 Duksal F, Alaygut D, Güven AS. et al. Neutrophil-lymphocyte ratio in children with familial Mediterranean fever: original article. Eur J Rheumatol 2015; 2 (01) 20-23
- 20 Uluca Ü, Ece A, Şen V. et al. Usefulness of mean platelet volume and neutrophil-to-lymphocyte ratio for evaluation of children with familial Mediterranean fever. Med Sci Monit 2014; 20: 1578-1582
- 21 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
- 22 Omranzadeh A, Baradaran A, Ghodsi A. et al. Comparing neutrophil to lymphocyte ratio between a group of familial Mediterranean fever (FMF) and a healthy control group. PROSPERO [Internet]. 2018 . Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018092613
- 23 JB Institute. JBI critical appraisal checklist for case control studies. Joanna Briggs Institute Reviewers' Manual. 2016
- 24 Kholoussi S, Kholoussi N, Zaki ME. et al. Immunological evaluation in patients with familial Mediterranean fever. Open Access Maced J Med Sci 2018; 6 (02) 310-313
- 25 Livneh A, Langevitz P, Zemer D. et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40 (10) 1879-1885
- 26 Yalçinkaya F, Özen S, Ozçakar ZB. et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009; 48 (04) 395-398
- 27 Daglar K, Kirbas A, Timur H. et al. Subclinical inflammation and simple blood parameters in pregnant with familial Mediterranean fever. J Clin Anal Med 2016; 7 (05) 634-638
- 28 Celikbilek M, Dogan S, Akyol L. et al. Neutrophil-lymphocyte ratio in patients with familial Mediterranean fever. J Clin Lab Anal 2015; 29 (01) 80-83
- 29 Özer S, Yılmaz R, Sönmezgöz E. et al. Simple markers for subclinical inflammation in patients with familial Mediterranean fever. Med Sci Monit 2015; 21: 298-303
- 30 Çakar M, Akhan M, Doğan T. et al. Investigation of the arterial stiffness and associated factors in patients with familial Mediterranean fever. Anatol J Cardiol 2017; 17 (02) 132-138
- 31 Ahsen A, Ulu MS, Yuksel S. et al. As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio. Inflammation 2013; 36 (06) 1357-1362
- 32 Bilginer Y, Akpolat T, Ozen S. Renal amyloidosis in children. Pediatr Nephrol 2011; 26 (08) 1215-1227
- 33 Savic S, Dickie LJ, Battellino M, McDermott MF. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol 2012; 24 (01) 103-112
- 34 Sakallı H, Kal O. Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever. Clin Rheumatol 2013; 32 (08) 1185-1190
- 35 Makay B, Türkyilmaz Z, Ünsal E. Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 2009; 28 (08) 975-978
- 36 Sharaiha RZ, Halazun KJ, Mirza F. et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011; 18 (12) 3362-3369
- 37 Azab B, Jaglall N, Atallah JP. et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology 2011; 11 (04) 445-452
- 38 Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med 2019; 39 (04) 345-357
- 39 Forget P, Khalifa C, Defour J-P, Latinne D, Van Pel M-C, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Res Notes 2017; 10 (01) 12
- 40 Bray C, Bell LN, Liang H. et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ 2016; 115 (06) 317-321
- 41 Li J, Chen Q, Luo X. et al. Neutrophil-to-lymphocyte ratio positively correlates to age in healthy population. J Clin Lab Anal 2015; 29 (06) 437-443
- 42 Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss III JF, Petraglia F. Inflammation and pregnancy. Reprod Sci 2009; 16 (02) 206-215
- 43 Eviatar T, Zaks N, Kukuy O, Livneh A, Lidar M. PW01–010–The effect of pregnancy on disease course in FMF. Pediatr Rheumatol Online J 2013; 11 (Suppl. 01) A63
- 44 Karacan İ, Uğurlu S, Tolun A, Tahir Turanlı E, Ozdogan H. Other autoinflammatory disease genes in an FMF-prevalent population: a homozygous MVK mutation and a novel heterozygous TNFRSF1A mutation in two different Turkish families with clinical FMF. Clin Exp Rheumatol 2017; 35 (06) (Suppl. 108) 75-81
- 45 Samuels J, Aksentijevich I, Torosyan Y. et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77 (04) 268-297
- 46 Booty MG, Chae JJ, Masters SL. et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit?. Arthritis Rheum 2009; 60 (06) 1851-1861
- 47 Balta S, Demirkol S, Unlu M, Arslan Z, Celik T. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. Br J Cancer 2013; 109 (12) 3125-3126
- 48 Corsia A, Georgin-Lavialle S, Hentgen V. et al. A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet J Rare Dis 2017; 12 (01) 54
- 49 Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev 2012; 12 (01) 31-37
- 50 Stroka KM, Hayenga HN, Aranda-Espinoza H. Human neutrophil cytoskeletal dynamics and contractility actively contribute to trans-endothelial migration. PLoS One 2013; 8 (04) e61377